Reflexion Pharmaceuticals is developing an entirely new class of molecules to overcome limitations of biologics. While protein-based drugs, especially monoclonal antibodies, have changed the world, there remains significant unmet need due to the inherent properties of antibodies, including proteolytic instability, immunogenicity, and large size. Our therapies are designed to have comparable affinity and specificity to antibodies while being “invisible” to the human body. These attributes enable nearly complete proteolytic stability, greatly reduced immunogenicity, and reduced off-target toxicity. Due to their smaller size, our therapies may be delivered at a higher molar dose and may be able to penetrate tissues better than antibodies. We believe that Reflexion’s platform can generate therapies that are more efficacious and better tolerated than current biologics.

Biotechnology

Health Care

Reflexion Pharmaceuticals

Reflexion Pharmaceuticals' headquarters in San Francisco, CA, United States

Description

People (2)

Greg Went

Paige Nittler

Jobs